Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide vs Bicalutamide in Metastatic Hormone Sensitive Prostate Cancer
NCT02058706Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- May 2014
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by Barbara Ann Karmanos Cancer Institute. Started May 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02058706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058706.